Promiliad, Spero Therapeutics, University of Connecticut deal

By WIR Staff | Jan 25, 2016 | 8:00 AM GMT

Promiliad granted Spero a worldwide, exclusive sublicense to develop and commercialize dihydrofolate

Read the full 126 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE